Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)

NCT03483961 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT03483961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03483961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Lead sponsor
Bavarian Nordic
Phase
Phase 2
Overall status
Completed
Start date
April 18, 2018
Completion date
September 21, 2020
Enrollment
445 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus infection